The current stock price of INGN is 7.03 USD. In the past month the price increased by 1.74%. In the past year, price decreased by -26.39%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.23 | 218.96B | ||
| ISRG | INTUITIVE SURGICAL INC | 68.09 | 207.82B | ||
| BSX | BOSTON SCIENTIFIC CORP | 33.1 | 144.75B | ||
| SYK | STRYKER CORP | 27.91 | 140.55B | ||
| BDX | BECTON DICKINSON AND CO | 14.06 | 57.87B | ||
| IDXX | IDEXX LABORATORIES INC | 56.57 | 56.96B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.12 | 49.40B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 19.02 | 39.76B | ||
| RMD | RESMED INC | 25.5 | 36.85B | ||
| DXCM | DEXCOM INC | 36.24 | 26.29B | ||
| PODD | INSULET CORP | 63.25 | 20.33B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.48 | 18.40B |
Inogen, Inc. is a medical technology company, which engages in the development, manufacture, and marketing of portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company is headquartered in Goleta, California and currently employs 766 full-time employees. The company went IPO on 2014-02-14. The company supports patient respiratory care by developing, manufacturing, and marketing portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. Its Inogen One and Inogen Rove systems concentrate the air around the patient to offer a source of supplemental oxygen with a battery and can be plugged into an outlet when at home, in a car, or in a public place with outlets available. Its Inogen One and Inogen Rove systems reduce the patient’s reliance on stationary concentrators and scheduled deliveries of tanks with a finite supply of oxygen. Inogen Connect is a wireless connectivity platform for the Inogen One G4, Inogen One G5, Inogen Rove 4, and Inogen Rove 6, consisting of a front-end mobile application for use by long-term oxygen therapy users. The company offers Simeox, which is an airway clearance device.
INOGEN INC
859 Ward Drive
Goleta CALIFORNIA 93117 US
CEO: Nabil Shabshab
Employees: 766
Phone: 18055620500
Inogen, Inc. is a medical technology company, which engages in the development, manufacture, and marketing of portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company is headquartered in Goleta, California and currently employs 766 full-time employees. The company went IPO on 2014-02-14. The company supports patient respiratory care by developing, manufacturing, and marketing portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. Its Inogen One and Inogen Rove systems concentrate the air around the patient to offer a source of supplemental oxygen with a battery and can be plugged into an outlet when at home, in a car, or in a public place with outlets available. Its Inogen One and Inogen Rove systems reduce the patient’s reliance on stationary concentrators and scheduled deliveries of tanks with a finite supply of oxygen. Inogen Connect is a wireless connectivity platform for the Inogen One G4, Inogen One G5, Inogen Rove 4, and Inogen Rove 6, consisting of a front-end mobile application for use by long-term oxygen therapy users. The company offers Simeox, which is an airway clearance device.
The current stock price of INGN is 7.03 USD. The price decreased by -2.63% in the last trading session.
INGN does not pay a dividend.
INGN has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
INOGEN INC (INGN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.94).
INOGEN INC (INGN) currently has 766 employees.
INOGEN INC (INGN) will report earnings on 2026-02-23, after the market close.
ChartMill assigns a technical rating of 3 / 10 to INGN. When comparing the yearly performance of all stocks, INGN is a bad performer in the overall market: 86.11% of all stocks are doing better.
ChartMill assigns a fundamental rating of 3 / 10 to INGN. While INGN seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months INGN reported a non-GAAP Earnings per Share(EPS) of -0.94. The EPS increased by 58.22% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -8.27% | ||
| ROE | -12.87% | ||
| Debt/Equity | 0 |
8 analysts have analysed INGN and the average price target is 13.26 USD. This implies a price increase of 88.62% is expected in the next year compared to the current price of 7.03.
For the next year, analysts expect an EPS growth of 36.25% and a revenue growth 7.88% for INGN